Human FVIII is inherently immunogenic in hemophilia A mice; consequently, all recipient mice that did not receive immunosuppresive treatment developed inhibitory anti–human FVIII antibodies, and there was no difference in the titer levels of FVIII antibodies between BDD and full-length FVIII vectors (Figure 3A, B). This evidence concerns the gene F8 and hemophilia.